View in EDS

Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study.

Saved in:
Bibliographic Details
Title: Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study.
Authors: Patel K; Swedish Cancer Institute, Seattle, WA., Vose JM; Division of Hematology, University of Nebraska Medical Center, Omaha, NE., Nasta SD; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA., Brown JR; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Maddocks KJ; The Ohio State University Comprehensive Cancer Center, Columbus, OH., Woyach JA; The Ohio State University Comprehensive Cancer Center, Columbus, OH., Shah NN; Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI., Fakhri B; Division of Hematology, Stanford University School of Medicine, Stanford, CA., Tessoulin B; Haematology Department, University Hospital of Nantes, Nantes, France., Ma S; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL., Jagadeesh D; Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH., Lech-Maranda E; Institute of Hematology and Transfusion Medicine, Warsaw, Poland., Coombs CC; Division of Hematology/Oncology, University of California Irvine, Irvine, CA., Patel MR; Florida Cancer Specialists, Sarasota, FL.; Sarah Cannon Research Institute, Nashville, TN., Rhodes JM; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ., Ujjani C; Division of Hematology and Oncology, Fred Hutchinson Cancer Research Center, Seattle, WA., Hoffmann MS; The University of Kansas Cancer Center, Kansas City, MO., Cheah CY; Linear Clinical Research and Sir Charles Gairdner Hospital, Nedlands, WA, Australia., Munir T; Department of Haematology, St James's University Hospital, Leeds, United Kingdom., Lewis D; University Hospitals Plymouth NHS, Plymouth, United Kingdom., Scarfò L; Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy., Eyre TA; Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center, Oxford, United Kingdom., Alencar A; University of Miami Sylvester Comprehensive Cancer Center, Miami, FL., Cohen JB; Winship Cancer Institute, Emory University, Atlanta, GA., Zelenetz AD; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY., Tsai DE; Eli Lilly and Company, Indianapolis, IN., Li M; Eli Lilly and Company, Indianapolis, IN., Bian Y; Eli Lilly and Company, Indianapolis, IN., Abada P; Eli Lilly and Company, Indianapolis, IN., Balbas M; Eli Lilly and Company, Indianapolis, IN., Zinzani PL; Istituto di Ematologia 'Seràgnoli,' Istituto di Ricovero e Cura a Carattere Scientifico Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.; Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy.
Source: Blood advances [Blood Adv] 2026 Apr 14; Vol. 10 (7), pp. 2441-2451.
Publication Type: Journal Article; Clinical Trial, Phase II; Clinical Trial, Phase I
Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41544219
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Patel+K%22">Patel K</searchLink>; Swedish Cancer Institute, Seattle, WA.<br /><searchLink fieldCode="AU" term="%22Vose+JM%22">Vose JM</searchLink>; Division of Hematology, University of Nebraska Medical Center, Omaha, NE.<br /><searchLink fieldCode="AU" term="%22Nasta+SD%22">Nasta SD</searchLink>; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.<br /><searchLink fieldCode="AU" term="%22Brown+JR%22">Brown JR</searchLink>; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Maddocks+KJ%22">Maddocks KJ</searchLink>; The Ohio State University Comprehensive Cancer Center, Columbus, OH.<br /><searchLink fieldCode="AU" term="%22Woyach+JA%22">Woyach JA</searchLink>; The Ohio State University Comprehensive Cancer Center, Columbus, OH.<br /><searchLink fieldCode="AU" term="%22Shah+NN%22">Shah NN</searchLink>; Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI.<br /><searchLink fieldCode="AU" term="%22Fakhri+B%22">Fakhri B</searchLink>; Division of Hematology, Stanford University School of Medicine, Stanford, CA.<br /><searchLink fieldCode="AU" term="%22Tessoulin+B%22">Tessoulin B</searchLink>; Haematology Department, University Hospital of Nantes, Nantes, France.<br /><searchLink fieldCode="AU" term="%22Ma+S%22">Ma S</searchLink>; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL.<br /><searchLink fieldCode="AU" term="%22Jagadeesh+D%22">Jagadeesh D</searchLink>; Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH.<br /><searchLink fieldCode="AU" term="%22Lech-Maranda+E%22">Lech-Maranda E</searchLink>; Institute of Hematology and Transfusion Medicine, Warsaw, Poland.<br /><searchLink fieldCode="AU" term="%22Coombs+CC%22">Coombs CC</searchLink>; Division of Hematology/Oncology, University of California Irvine, Irvine, CA.<br /><searchLink fieldCode="AU" term="%22Patel+MR%22">Patel MR</searchLink>; Florida Cancer Specialists, Sarasota, FL.; Sarah Cannon Research Institute, Nashville, TN.<br /><searchLink fieldCode="AU" term="%22Rhodes+JM%22">Rhodes JM</searchLink>; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.<br /><searchLink fieldCode="AU" term="%22Ujjani+C%22">Ujjani C</searchLink>; Division of Hematology and Oncology, Fred Hutchinson Cancer Research Center, Seattle, WA.<br /><searchLink fieldCode="AU" term="%22Hoffmann+MS%22">Hoffmann MS</searchLink>; The University of Kansas Cancer Center, Kansas City, MO.<br /><searchLink fieldCode="AU" term="%22Cheah+CY%22">Cheah CY</searchLink>; Linear Clinical Research and Sir Charles Gairdner Hospital, Nedlands, WA, Australia.<br /><searchLink fieldCode="AU" term="%22Munir+T%22">Munir T</searchLink>; Department of Haematology, St James's University Hospital, Leeds, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Lewis+D%22">Lewis D</searchLink>; University Hospitals Plymouth NHS, Plymouth, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Scarfò+L%22">Scarfò L</searchLink>; Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Eyre+TA%22">Eyre TA</searchLink>; Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center, Oxford, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Alencar+A%22">Alencar A</searchLink>; University of Miami Sylvester Comprehensive Cancer Center, Miami, FL.<br /><searchLink fieldCode="AU" term="%22Cohen+JB%22">Cohen JB</searchLink>; Winship Cancer Institute, Emory University, Atlanta, GA.<br /><searchLink fieldCode="AU" term="%22Zelenetz+AD%22">Zelenetz AD</searchLink>; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.<br /><searchLink fieldCode="AU" term="%22Tsai+DE%22">Tsai DE</searchLink>; Eli Lilly and Company, Indianapolis, IN.<br /><searchLink fieldCode="AU" term="%22Li+M%22">Li M</searchLink>; Eli Lilly and Company, Indianapolis, IN.<br /><searchLink fieldCode="AU" term="%22Bian+Y%22">Bian Y</searchLink>; Eli Lilly and Company, Indianapolis, IN.<br /><searchLink fieldCode="AU" term="%22Abada+P%22">Abada P</searchLink>; Eli Lilly and Company, Indianapolis, IN.<br /><searchLink fieldCode="AU" term="%22Balbas+M%22">Balbas M</searchLink>; Eli Lilly and Company, Indianapolis, IN.<br /><searchLink fieldCode="AU" term="%22Zinzani+PL%22">Zinzani PL</searchLink>; Istituto di Ematologia 'Seràgnoli,' Istituto di Ricovero e Cura a Carattere Scientifico Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.; Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101698425%22">Blood advances</searchLink> [Blood Adv] 2026 Apr 14; Vol. 10 (7), pp. 2441-2451.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase II; Clinical Trial, Phase I
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Society+of+Hematology%22">American Society of Hematology </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101698425 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>2473-9537 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2224739529%22">24739529 </searchLink><i>NLM ISO Abbreviation: </i>Blood Adv <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41544219
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1182/bloodadvances.2025017489
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 2441
    Titles:
      – TitleFull: Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Patel K
      – PersonEntity:
          Name:
            NameFull: Vose JM
      – PersonEntity:
          Name:
            NameFull: Nasta SD
      – PersonEntity:
          Name:
            NameFull: Brown JR
      – PersonEntity:
          Name:
            NameFull: Maddocks KJ
      – PersonEntity:
          Name:
            NameFull: Woyach JA
      – PersonEntity:
          Name:
            NameFull: Shah NN
      – PersonEntity:
          Name:
            NameFull: Fakhri B
      – PersonEntity:
          Name:
            NameFull: Tessoulin B
      – PersonEntity:
          Name:
            NameFull: Ma S
      – PersonEntity:
          Name:
            NameFull: Jagadeesh D
      – PersonEntity:
          Name:
            NameFull: Lech-Maranda E
      – PersonEntity:
          Name:
            NameFull: Coombs CC
      – PersonEntity:
          Name:
            NameFull: Patel MR
      – PersonEntity:
          Name:
            NameFull: Rhodes JM
      – PersonEntity:
          Name:
            NameFull: Ujjani C
      – PersonEntity:
          Name:
            NameFull: Hoffmann MS
      – PersonEntity:
          Name:
            NameFull: Cheah CY
      – PersonEntity:
          Name:
            NameFull: Munir T
      – PersonEntity:
          Name:
            NameFull: Lewis D
      – PersonEntity:
          Name:
            NameFull: Scarfò L
      – PersonEntity:
          Name:
            NameFull: Eyre TA
      – PersonEntity:
          Name:
            NameFull: Alencar A
      – PersonEntity:
          Name:
            NameFull: Cohen JB
      – PersonEntity:
          Name:
            NameFull: Zelenetz AD
      – PersonEntity:
          Name:
            NameFull: Tsai DE
      – PersonEntity:
          Name:
            NameFull: Li M
      – PersonEntity:
          Name:
            NameFull: Bian Y
      – PersonEntity:
          Name:
            NameFull: Abada P
      – PersonEntity:
          Name:
            NameFull: Balbas M
      – PersonEntity:
          Name:
            NameFull: Zinzani PL
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 14
              M: 04
              Text: 2026 Apr 14
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 2473-9537
          Numbering:
            – Type: volume
              Value: 10
            – Type: issue
              Value: 7
          Titles:
            – TitleFull: Blood advances
              Type: main
ResultId 1